Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Third-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in Bank of America Securities 2022 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces First-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback